
A research team led by Lucía Chávez-Gutiérrez, PhD, at the VIB-KU Leuven Center for Brain & Disease Research has developed a method to predict the onset of familial Alzheimer’s disease (AD) by analyzing genetic mutations in key proteins involved in amyloid-beta (Aβ) processing. Published in Molecular Neurodegeneration, the study links biochemical changes in Aβ peptide profiles caused by mutations in PSEN1, PSEN2, and APP to the age of disease onset, establishing a predictive model that could enhance clinical diagnosis and guide treatment strategies.
“In familial Alzheimer’s disease, patients are often seen to have spontaneous genetic mutations, but until now, doctors have not been able to provide patients more specific information about them,” said first author Chávez-Gutiérrez. “We have developed a method to experimentally test how likely a mutation is to cause the disease, as well as to predict disease onset.”
For this study, the investigators profiled 28 PSEN2 and 19 APP mutations, building on earlier work that had shown a strong correlation between PSEN1 mutations and the age of symptom onset. These genes are associated with autosomal dominant Alzheimer’s disease (ADAD), a rare form of AD characterized by early onset, usually before age 65.
In prior work, Chávez-Gutiérrez’s lab demonstrated that PSEN1 mutations impaired γ-secretase enzyme activity, reducing its ability to process Aβ peptides into shorter forms that have lesser deleterious effects on the brain. The current study included analysis of the PSEN2 and APP proteins, which showed that similar impairments in γ-secretase activity correlate linearly with the age of AD onset.
When data across all three genes were combined, the study found “parallel but shifted lines,” indicating a common mechanism—γ-secretase dysfunction—that operates on a gene-specific timeline. “This study supports a unified model of ADAD pathogenesis wherein γ-secretase dysfunction and the resulting shifts in Aβ profiles are central to disease onset across all causal genes.”
The researchers found they could quantify the effect of each gene’s mutations on disease onset. Compared to PSEN1, PSEN2 mutations delayed symptoms by an average of 27 years and APP mutations by eight years. “Our data predicts that a 12% shift in Aβ profile could delay the age of onset in familial Alzheimer’s disease by up to five years,” said Chávez-Gutiérrez. The hope is that such information could help clinicians delay the onset of AD by the administration of γ-secretase modulators (GSMs), which have shown promise as an AD treatment.
The new model also distinguishes between mutation types. Some variants previously classified as benign or of uncertain significance (VUS) were found to significantly alter Aβ processing, while others associated with later onset showed minimal effect on γ-secretase function.
Significantly, the predictive model provides not only estimates for age of onset, but also a basis to identify carriers whose clinical presentation deviates from predictions. These deviations may point to the influence of other genetic or environmental factors. “Our biochemical measurements provide reference points against which to evaluate clinical AAO (age at onset) variability and potentially possible therapeutic effects of disease-modifying treatments,” the researchers wrote.
The researchers did note some limitations of the current work, noting that the correlation strength for PSEN2 and APP mutations is weaker than for PSEN1, suggesting that other mechanisms such as transcript stability, somatic gene recombination, or environmental exposures may significantly influence disease onset in some carriers.
But with these new findings, the team is now looking to develop new therapeutic approaches for this form of AD. “We have developed a predictive model for age of onset that could pave the way for personalized approaches to managing familial Alzheimer’s,” said Sara Gutiérrez Fernández, a doctoral researcher at VIB-KU Leuven Center for Brain & Disease Research. “In the future, this may help clinicians to more effectively design strategies for early diagnosis and treatment for patients with genetic forms of the disease. Our lab is now focused on doing more research with the aim of developing therapies using this model.”





